Epoxygenated fatty acids and soluble epoxide hydrolase inhibition: novel mediators of pain reduction.
The soluble epoxide hydrolase (sEH) enzyme was discovered while investigating the metabolism of xenobiotic compounds in the Casida laboratory. However, an endogenous role of sEH is to regulate the levels of a group of potent bioactive lipids, epoxygenated fatty acids (EFAs), that have pleiotropic biological activities. The EFAs, in particular the arachidonic acid derived epoxy eicosatrienoic acids (EETs), are established autocrine and paracrine messengers. The most recently discovered outcome of inhibition of sEH and increased EFAs is their effects on the sensory system and in particular their ability to reduce pain. The inhibitors of sEH block both inflammatory and neuropathic pain. Elevation of EFAs, in both the central and peripheral nervous systems, blocks pain. Several laboratories have now published a number of potential mechanisms of action for the pain-reducing effects of EFAs. This paper provides a brief history of the discovery of the sEH enzyme and argues that inhibitors of sEH through several independent mechanisms display pain-reducing effects.
Department of Entomology and University of California Davis Cancer Center, University of California-Davis, Davis, California 95616, United States.
Karen
K
Wagner
Bora
B
Inceoglu
Sarjeet S
SS
Gill
Bruce D
BD
Hammock
D000698:Analgesia; D000893:Anti-Inflammatory Agents; D004851:Epoxide Hydrolases / Q000037:antagonists & inhibitors* / Q000502:physiology*; D004852:Epoxy Compounds; D005227:Fatty Acids / Q000502:physiology*; D007249:Inflammation; D009420:Nervous System / Q000187:drug effects; D009619:Nociceptors; D010146:Pain
D000893:Anti-Inflammatory Agents; D004852:Epoxy Compounds; D005227:Fatty Acids; D004851:Epoxide Hydrolases